The Manpei Suzuki Diabetes Foundation is pleased to announce the 2009 winner of the International Prize: Donald F. Steiner, MD, A. N. Pritzker Distinguished Service Professor Emeritus, Departments of Medicine and Biochemistry and Molecular Biology, The University of Chicago, USA. The Prize was inaugurated in 2008 to commemorate the 15th anniversary of the Manpei Suzuki Diabetes Foundation, honoring those who have enlightened researchers in the field of diabetes around the world with their original and excellent scientific achievements. Dr. Steiner will be awarded a Certificate of Honor, US$150, 000, and a Japanese objet d'art at the award ceremony on March 2, 2010.
A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics. It was believed that amyloid fibrils - rope-like structures made up of proteins sometimes known as fibres - are inert, but that there may be toxic phases during their formation which can damage cells and cause disease. But in a paper published 04 December 2009 in the Journal of Biological Chemistry, scientists at the University of Leeds have shown that amyloid fibres are in fact toxic - and that the shorter the fibre, the more toxic it becomes.
According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have abnormal insulin resistance. Having abnormal insulin resistance appears to negatively affect heart, blood vessel and exercise function in this population. Type 1 diabetes often begins in childhood. Patients with type 2 diabetes have their insulin resistance measured routinely, but this is currently not common practice in treating patients with type 1 diabetes--especially those with normal weight. Because insulin resistance is known to contribute to cardiovascular disease in type 2 diabetes researchers in this study investigated whether insulin resistance has a similar effect on adolescents with type 1 diabetes.
Sinai Hospital of Baltimore takes an innovative approach to help people with diabetes mange their disease by opening the Diabetes Resource Center at Sinai. Participants who attend the center learn how to set and achieve successful medical and lifestyle goals with practical advice and emotional support. "In our program, people learn how they can better handle their treatment regimen, " says Sally Pinkstaff, M.D., Ph.D., director of the Diabetes Resource Center at Sinai. "Having the knowledge and skills to understand and take action against this disease are essential components to successfully living with diabetes." Education is crucial when coping with the disease.
Researchers from LSU Health Sciences Center New Orleans School of Public Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School, have found for the first time that drinking more than 5 servings of sugar- sweetened cola a week prior to pregnancy appears to significantly elevate the risk of developing diabetes during pregnancy. Liwei Chen, MD, PhD, Assistant Professor of Epidemiology at LSU Health Sciences Center New Orleans School of Public Health, is the lead author of the paper, A Prospective Study of Pre-Gravid Sugar-Sweetened Beverage Consumption and the Risk of Gestational Diabetes Mellitus, that will be published in the December 2009 issue of Diabetes Care and is available online now at http://diabetes.
Diabetes UK's Measure Up Roashow 2009 has encouraged thousands of people in the UK to measure their waists and find out if they are at risk of developing Type 2 diabetes. So far, the Roadshow has handed out 71, 000 leaflets and flyers and risk assessed 4, 527 people, out of which 1, 504 have been referred to their GP to find out of they have Type 2 diabetes. The Measure Up Roadshow, which kicked off in June, is touring the country until the end of December in a bid to help people find out more about Type 2 diabetes and its risk factors. These include: - having a large waist (37 inches or more for men, except those of South Asian origin who are at risk at 35 inches or more, and 31.
Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoints In Head-to-Head Study With Sitagliptin Januvia R And Versus Placebo
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen's research and developed by Roche. T-emerge 1 (subcutaneous weekly taspoglutide versus placebo in treatment-naĆ ve patients) and T-emerge 4 (subcutaneous weekly taspoglutide versus sitagliptin versus placebo) both met their respective primary endpoints of change in HbA1c. In both studies taspoglutide was generally well tolerated.
A group of endocrinologists in Sydney have observed that extremely ill patients tend to own actual low levels of Vitamin D. The sicker they are, the lower the levels. Dr Paul Lee, Professor John Eisman and Associate Professor Jackie Center, researchers at Sydney's Garvan Institute of Medical Research, examined a cohort of 42 Intensive Care Unit (ICU) patients. Forty-five percent turned out to be Vitamin D deficient. These findings were published as a letter in the April 30, 2009 investigation of the New Great britain Log of Medicine. "Until now, the medical local has thought of Vitamin D deficiency as a chronic condition, " said Dr Lee. "Little is conscious about its acute complications.
Apidra R SoloSTAR R , The Easy-to-Use Insulin Delivery Slogan From Sanofi Aventis, Instanter Available In The United States
Sanofi-aventis U.S. announced that Apidra(R) SoloSTAR(R) (insulin glulisine [rDNA origin] injection), a prefilled disposable pen containing the rapid-acting insulin analog Apidra(R), is double time available in the United States. Apidra(R) is indicated to boost glycemic control in adults and children (4 elderliness and older) with type 1 diabetes or adults with type 2 diabetes. "Sanofi-aventis is dedicated to providing innovative tools to patients with diabetes that can hand support some of the challenges of blood sugar management, " said Jerry Durso, Vise President, Specialized Therapeutics Business Unit, sanofi-aventis U.S. "Apidra(R) SoloSTAR(R) provides patients with a convenient preference for administering their Apidra(R).
The International Diabetes Federation (IDF) announced they have moved to late offices in Brussels. IDF is a federation of over 200 diabetes associations in over 160 countries and has its headquarters in Brussels, Belgium. The Federation's daily grind has expanded exponentially to meet the trial of the growing global diabetes epidemic. Diabetes organizations sorrounding the world are applying for membership; the Executive Office in Brussels has expanded to collar donkeywork in key areas of diabetes education, epidemiology and health economics. IDF extremely continues to constitution on the foundation of its advocacy, awareness campaigns - Nature Diabetes Day and Unite for Diabetes - and World Diabetes Congresses.